Equities research analysts expect that ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) will post $48.46 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for ANI Pharmaceuticals’ earnings. The lowest sales estimate is $48.41 million and the highest is $48.50 million. ANI Pharmaceuticals reported sales of $38.53 million in the same quarter last year, which indicates a positive year over year growth rate of 25.8%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that ANI Pharmaceuticals will report full year sales of $48.46 million for the current financial year, with estimates ranging from $183.23 million to $183.40 million. For the next fiscal year, analysts expect that the business will report sales of $215.95 million per share, with estimates ranging from $205.90 million to $226.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow ANI Pharmaceuticals.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.19. The business had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The firm’s revenue for the quarter was up 43.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.11 earnings per share.

A number of equities analysts recently commented on ANIP shares. Guggenheim reaffirmed a “buy” rating and set a $80.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, July 4th. ValuEngine lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 price target on shares of ANI Pharmaceuticals in a research report on Wednesday, August 9th. BidaskClub lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $65.33.

A number of large investors have recently added to or reduced their stakes in ANIP. Mesirow Financial Investment Management Inc. bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $506,000. Dynamic Technology Lab Private Ltd bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $210,000. Raymond James Financial Services Advisors Inc. increased its holdings in ANI Pharmaceuticals by 67.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 9,493 shares of the specialty pharmaceutical company’s stock valued at $444,000 after buying an additional 3,837 shares during the period. Dana Investment Advisors Inc. increased its holdings in ANI Pharmaceuticals by 0.8% in the 2nd quarter. Dana Investment Advisors Inc. now owns 42,720 shares of the specialty pharmaceutical company’s stock valued at $1,999,000 after buying an additional 341 shares during the period. Finally, Western Standard LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $693,000. 55.86% of the stock is currently owned by institutional investors and hedge funds.

Shares of ANI Pharmaceuticals (ANIP) opened at 50.09 on Friday. The company has a 50-day moving average of $46.71 and a 200-day moving average of $47.94. ANI Pharmaceuticals has a 1-year low of $42.23 and a 1-year high of $69.85. The company has a market cap of $582.95 million, a PE ratio of 109.61 and a beta of 3.10.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/17/ani-pharmaceuticals-inc-anip-expected-to-post-quarterly-sales-of-48-46-million-2.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.